Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production

Metformin is a widely used and well-tolerated anti-diabetic drug that can reduce cancer risk and improve the prognosis of certain malignancies. However, the mechanism underlying its anti-cancer effect is still unclear. We studied the anti-cancer activity of metformin on colorectal cancer (CRC) by us...

Descripción completa

Detalles Bibliográficos
Autores principales: Mogavero, Angela, Maiorana, Maria Valeria, Zanutto, Susanna, Varinelli, Luca, Bozzi, Fabio, Belfiore, Antonino, Volpi, Chiara C., Gloghini, Annunziata, Pierotti, Marco A., Gariboldi, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700100/
https://www.ncbi.nlm.nih.gov/pubmed/29167573
http://dx.doi.org/10.1038/s41598-017-16149-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700100/
https://www.ncbi.nlm.nih.gov/pubmed/29167573
http://dx.doi.org/10.1038/s41598-017-16149-z

Ejemplares similares